Edgestream Partners L.P. purchased a new stake in Medtronic plc (NYSE:MDT – Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 3,032 shares of the medical technology company’s stock, valued at approximately $239,000.
Several other hedge funds also recently made changes to their positions in MDT. LifeSteps Financial Inc. purchased a new position in Medtronic during the first quarter worth about $27,000. Lynx Investment Advisory purchased a new position in Medtronic during the second quarter worth about $28,000. Tributary Capital Management LLC purchased a new position in Medtronic during the first quarter worth about $33,000. Fortis Group Advisors LLC grew its position in Medtronic by 100.0% during the fourth quarter. Fortis Group Advisors LLC now owns 460 shares of the medical technology company’s stock worth $38,000 after buying an additional 230 shares in the last quarter. Finally, Riverview Trust Co purchased a new position in Medtronic during the first quarter worth about $39,000. 82.06% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several equities analysts recently commented on the company. Daiwa America upgraded Medtronic to a “strong-buy” rating in a research report on Friday, August 23rd. Needham & Company LLC restated a “hold” rating on shares of Medtronic in a research report on Tuesday, August 20th. Stifel Nicolaus upped their price objective on Medtronic from $85.00 to $87.00 and gave the stock a “hold” rating in a report on Wednesday, August 21st. Barclays upped their price objective on Medtronic from $104.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, August 22nd. Finally, Robert W. Baird upped their price objective on Medtronic from $82.00 to $90.00 and gave the stock a “neutral” rating in a report on Wednesday, August 21st. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $92.92.
Medtronic Trading Up 0.6 %
MDT opened at $89.86 on Tuesday. The business has a 50 day simple moving average of $85.03 and a two-hundred day simple moving average of $82.99. The firm has a market capitalization of $115.22 billion, a price-to-earnings ratio of 32.68, a PEG ratio of 2.57 and a beta of 0.84. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.13 and a quick ratio of 1.61. Medtronic plc has a one year low of $68.84 and a one year high of $91.49.
Medtronic (NYSE:MDT – Get Free Report) last released its quarterly earnings results on Tuesday, August 20th. The medical technology company reported $1.23 EPS for the quarter, beating analysts’ consensus estimates of $1.20 by $0.03. The business had revenue of $7.97 billion during the quarter, compared to analyst estimates of $7.90 billion. Medtronic had a return on equity of 13.68% and a net margin of 12.06%. Medtronic’s quarterly revenue was up 3.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.20 EPS. Analysts predict that Medtronic plc will post 5.46 EPS for the current year.
Medtronic Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, October 11th. Shareholders of record on Friday, September 27th will be given a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a yield of 3.12%. The ex-dividend date of this dividend is Friday, September 27th. Medtronic’s payout ratio is 101.82%.
Medtronic Company Profile
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
Recommended Stories
- Five stocks we like better than Medtronic
- Investing in Construction Stocks
- The Average 401k Balance by Age Explained
- How Can Investors Benefit From After-Hours Trading
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- Transportation Stocks Investing
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic plc (NYSE:MDT – Free Report).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.